Large stock price swings like Medpace's recent 55% jump are typically driven by identifiable factors such as short squeezes or concentrated trading rather than pure market randomness. Investors should distinguish between moves based on corporate developments versus those fueled by momentum or retail trading, as each carries different risks and implications for long-term value.
Medpace Holdings, Inc. Common Stock (MEDP)
Common Stock · Currency in USD · XNAS
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Company Info
SIC8731
Composite FIGIBBG0065B7K59
CIK0001668397
IPOAug 11, 2016
Sectorservices-commercial physical & biological research
Highlights
Market Cap$14.14B
EPS$15.80
P/E Ratio31.82
Revenue$2.53B
Gross Profit$787.76M
Net Income$444.54M
Employees6,200
WSO28,381,283
Phone(513) 579-9911
Websitehttps://www.medpace.com
Related Tickers
Analysis
Share Price Chart
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Medpace Holdings, Inc. Common Stock, comparing it to the performance of the S&P 500 index.
All prices have been adjusted for splits and dividends.
Returns By Period
Medpace Holdings, Inc. Common Stock (MEDP) has returned -10.80% so far this year and 78.59% over the past 12 months. Looking at the last ten years, MEDP has achieved an annualized return of 33.29%, outperforming the Benchmark (SPY), which averaged 12.23% per year.
MEDP
1M8.26%
6M-7.20%
YTD-10.80%
1Y78.59%
5Y23.61%
10Y33.29%
Benchmark (SPY)
1M-3.85%
6M-2.35%
YTD-4.36%
1Y34.06%
5Y9.80%
10Y12.23%
Monthly Returns
The table below presents the monthly returns of Medpace Holdings, Inc. Common Stock (MEDP) with color gradation from worst to best to easily spot seasonal factors.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.26% | -21.59% | 7.91% | 3.76% | ||||||||
| 2025 | 4.25% | -4.72% | -6.96% | 0.83% | -3.67% | 6.80% | 35.86% | 12.09% | 8.38% | 13.68% | 1.29% | -4.61% |
| 2024 | -4.15% | 35.81% | 1.67% | -4.11% | -0.11% | 5.23% | -7.52% | -7.38% | -6.19% | -5.85% | 8.14% | -2.20% |
| 2023 | 4.12% | -12.78% | -3.40% | 6.88% | 2.82% | 16.09% | 4.63% | 7.23% | -11.34% | 0.43% | 12.09% | 13.37% |
| 2022 | -18.36% | -14.05% | 6.53% | -18.77% | 7.96% | 3.94% | 13.85% | -12.55% | 7.98% | 40.68% | -3.83% | 0.77% |
| 2021 | -5.14% | 21.03% | -0.37% | 2.97% | -0.54% | 5.46% | -0.92% | 2.70% | 3.98% | 19.26% | -8.83% | 4.02% |
| 2020 | 0.66% | 4.21% | -19.26% | 13.44% | 18.11% | 0.32% | 27.32% | 7.18% | -14.24% | -1.11% | 13.67% | 7.87% |
| 2019 | 23.51% | -14.67% | 6.41% | -5.50% | -3.37% | 21.15% | 18.94% | 2.17% | 5.31% | -13.01% | 4.31% | 9.42% |
| 2018 | 0.60% | -12.41% | 8.52% | 6.48% | 3.64% | 1.82% | 43.52% | -2.57% | -0.48% | -13.57% | 18.01% | -16.44% |
| 2017 | -4.20% | -16.88% | 2.93% | 5.70% | -12.74% | 3.91% | -5.54% | 12.55% | -2.89% | 16.98% | -6.17% | 9.55% |
| 2016 | 0.36% | 5.25% | -3.56% | 22.99% | 0.64% |
Performance Indicators
The charts below present risk-adjusted performance metrics for Medpace Holdings, Inc. Common Stock (MEDP) and compare them to a Benchmark (SPY). These indicators evaluate an investment's returns against its associated risks.
Sharpe ratio
Sortino ratio
Omega ratio
Calmar ratio
Martin ratio
sharpe ratio
The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.
These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns.
The chart below shows the rolling Sharpe ratio of MEDP compared to the benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.
Volatility Chart
The current Medpace Holdings, Inc. Common Stock volatility is 2.34%, representing the standart deviation of percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. It shows the maximum percentage drop from a peak to a trough over a specified period, indicating the risk of significant losses.
Although chart shows positive values, it represents the percentage drop from the peak, so a value of 10% means the portfolio has dropped 10% from its highest point.
Income Statement
The income statement provides a summary of a company's revenues, expenses, and profits over a specific period. It shows how much money the company earned (revenues) and how much it spent (expenses), leading to the net income or profit. This statement is crucial for understanding a company's financial performance and profitability.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities And Equity (USD) | 1.98B | 2.10B | 1.66B | 1.35B | 1.66B | 1.39B | 1.14B | 967.93M | 950.72M | 979.11M |
| Equity Attributable To Parent (USD) | 459.07M | 825.55M | 558.95M | 386.39M | 952.93M | 805.78M | 726.28M | 589.70M | 503.53M | 610.71M |
| Equity Attributable To Noncontrolling Interest (USD) | - | - | - | - | - | - | - | - | - | - |
| Equity (USD) | 459.07M | 825.55M | 558.95M | 386.39M | 952.93M | 805.78M | 726.28M | 589.70M | 503.53M | 610.71M |
| Commitments and Contingencies (USD) | - | - | - | - | - | - | - | - | - | - |
| Other Non-current Liabilities (USD) | - | - | - | - | - | - | - | - | - | 34.79M |
| Long-term Debt (USD) | - | - | - | - | - | - | - | - | - | 165.00M |
| Noncurrent Liabilities (USD) | 172.65M | 170.77M | 172.75M | 162.64M | 149.79M | 144.79M | 73.79M | 121.20M | 254.48M | 199.79M |
| Other Current Liabilities (USD) | 1.24B | 987.10M | 817.44M | 699.20M | 473.69M | 373.35M | 286.48M | 208.95M | 156.33M | 136.24M |
| Wages (USD) | 80.14M | 84.93M | 75.82M | 71.20M | 57.85M | 40.21M | 34.12M | 31.34M | 19.71M | 21.45M |
| Accounts Payable (USD) | 28.14M | 32.53M | 31.87M | 33.07M | 25.68M | 26.55M | 22.40M | 16.74M | 16.67M | 10.91M |
| Current Liabilities (USD) | 1.34B | 1.10B | 925.13M | 803.47M | 557.22M | 440.11M | 343.00M | 257.03M | 192.71M | 168.60M |
| Liabilities (USD) | 1.52B | 1.28B | 1.10B | 966.11M | 707.01M | 584.90M | 416.79M | 378.23M | 447.19M | 368.40M |
| Other Non-current Assets (USD) | 821.37M | 913.66M | 906.60M | 870.68M | 834.51M | 785.54M | 724.40M | 668.39M | 673.27M | 665.98M |
| Intangible Assets (USD) | 33.42M | 34.37M | 35.81M | 38.01M | 41.36M | 46.47M | 54.35M | 69.18M | 98.74M | 136.07M |
| Fixed Assets (USD) | 131.06M | 123.62M | 120.59M | 109.85M | 93.15M | 85.02M | 47.29M | 52.26M | 48.74M | 43.81M |
| Noncurrent Assets (USD) | 985.85M | 1.07B | 1.06B | 1.02B | 969.02M | 917.03M | 826.04M | 789.82M | 820.75M | 845.86M |
| Other Current Assets (USD) | 587.55M | 732.79M | 295.43M | 80.56M | 504.48M | 312.69M | 161.37M | 44.67M | 46.89M | 53.48M |
| Accounts Receivable (USD) | 402.08M | 296.44M | 298.40M | 253.40M | 186.43M | 160.96M | 155.66M | 133.45M | 83.08M | 79.77M |
| Current Assets (USD) | 989.62M | 1.03B | 593.83M | 333.96M | 690.91M | 473.65M | 317.03M | 178.11M | 129.97M | 133.25M |
| Assets (USD) | 1.98B | 2.10B | 1.66B | 1.35B | 1.66B | 1.39B | 1.14B | 967.93M | 950.72M | 979.11M |
News and Insights
Ten large-cap stocks experienced significant declines last week. Pinterest fell 21.73% after missing Q4 earnings and issuing weak Q1 guidance with multiple downgrades. DraftKings dropped 18.65% following disappointing Q4 results and below-estimate FY26 guidance. Other major losers included Astera Labs (down 23.74%), Medpace (down 20.69%), Zillow (down 20.89%), and Flutter Entertainment (down 18.88%), driven by earnings misses, analyst downgrades, and broader tech sector concerns about AI trade profitability.
The global innovative drug CRO market is projected to grow from USD 59.63 billion in 2026 to USD 96.06 billion by 2035, with a 5.44% CAGR, driven by increasing R&D costs, clinical trial complexities, and technological advancements.
Why Medpace Popped 13% This Weekpositive
Medpace, a clinical research organization, saw strong revenue growth and a recovering clinical trial industry, leading to a 13% stock price increase after reporting impressive Q3 earnings with 24% year-over-year revenue growth.
Clinical research organization Medpace reported strong Q3 earnings, beating consensus estimates with $3.86 per share and $659.9 million in revenue, representing a 23.7% year-over-year increase. The company raised fiscal 2025 guidance and saw significant new business awards.
The global clinical trial biorepository and archiving solutions market is projected to grow from USD 4.76 billion in 2025 to USD 9.69 billion by 2034, with a CAGR of 8.21%. North America dominates the market, while Asia Pacific is expected to experience the fastest growth, driven by advancements in biobanking technologies and increasing demand for personalized medicine.
Medpace, a clinical contract research organization, reported strong Q2 2025 earnings, exceeding analyst expectations with 14.2% revenue growth and raised full-year guidance despite sector challenges.
The global preclinical Contract Research Organization (CRO) market is projected to grow from USD 6.8 billion in 2025 to USD 14.34 billion by 2034, driven by increased pharmaceutical R&D, technological advancements, and demand for specialized research services.
The global regulatory affairs outsourcing market is expected to grow significantly from 2024 to 2030, driven by the globalization of biopharmaceutical and medical device companies and the need for specialized regulatory expertise. Technological advancements in regulatory processes are also shaping the market.
Medpace Holdings, Inc. reported a lower-than-expected net book-to-bill ratio in Q3 2024, leading to a 7% drop in its stock price. The law firm Kessler Topaz Meltzer & Check is investigating potential securities law violations on behalf of Medpace investors.